|
EPR Archived News |
Astral Pharmaceutical Industries Vadodara, India Will Enter United States Market Very Soon
Released on: July 24, 2010, 3:40 am Astral Pharmaceutical Industries, a state of the art, manufacturing facility for Sterile Antibiotic powder injectables, at Vadodara, India is a specialized and dedicated site ,having independent manufacturing infrastructure for Cephalosporin and Penicillin Range of powder Injectable Drug Products. The company headed by President & CEO Dr. Dushyant R. Patel has highly successful track record of more than a decade ,catering to the domestic, LATAM, SEA and CIS markets for the powder injectable drug products. Astral is a leading player in this segment and has been associated with MNC’s and large Indian Pharma companies. Both the manufacturing lines, one for Cephalosporin Injectable Drug Products and other for Penicillin range of injectable Drug Products have been recently granted approval by US FDA. Prior to the facility approval from USFDA Astral has received several Regulatory accreditation such as HPFBI-Canada, TGA-Australia, MCC-South Africa, ANVISA-Brazil over and above accreditation from several Semi regulated countries. Astral will soon be entering the US market in strategic alliance with Chicago based Sagent Pharmaceutical Inc. with whom more than 15 ANDAs have been filed. While the development projects for more ANDA’s are in pipeline, Astral is actively working on consolidating its strong regulatory profile for entry into EU markets apart from fast tracking its filings for Canada, Australia and New Zealand markets. Continuous technology up gradation and focused development in the core competency area of sterile manufacturing operations has been the strategy of growth. Astral is poised to expand its operations in the field of specialized and niche sterile dosage forms for critical care segments and hospital products. For further information visit http://www.astralpharma.com or contact Dr. Dushyant Patel at dushyantpatel@astralpharma.com. Contact Details: Astral Pharmaceutical Industries
|
|
2022
